We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Alliance Pharma Plc | LSE:APH | London | Ordinary Share | GB0031030819 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 33.70 | 33.70 | 33.85 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 167.42M | 936k | 0.0017 | 199.12 | 182.84M |
TIDMAPH
RNS Number : 3666Y
Alliance Pharma PLC
02 January 2024
For immediate release 02 January 2024
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Block Listing Six Monthly Return
Name of applicant: ALLIANCE PHARMA PLC Names of schemes: a) The Alliance Pharma plc Approved Share Option Plan 2005 b) The Alliance Pharma plc Share Option Plan 2006 c) The Alliance Pharma plc Company Share Option Plan 2015 d) The Alliance Pharma plc Long-Term Incentive Plan 2019 --------------------------------------------------------------- Period of return: From: 28 June 2023 To: 31 December 2023 ---------------------- ----------------------- ------- ----------------------------- Number of securities originally admitted at date of 25,000,000 ordinary shares of 1p each admission: 28 June 2017 --------------------------------------------------------------- Balance of unallotted securities under schemes from a) 57,922 previous return: b) 2,487,746 c) 9,572,622 d) 1,341,116 --------------------------------------------------------------- Plus: The amount by which the block schemes have a) Nil been increased since the date of the last b) Nil return (if any increase has been applied for): c) Nil d) Nil --------------------------------------------------------------- Less: Number of securities issued/allotted under a) 0 schemes during period: b) 14,239 c) 0 d) 225,618 --------------------------------------------------------------- Equals: Balance under schemes not yet a) 57,922 issued/allotted at end of period: b) 2,473,507 c) 9,572,622 d) 1,115,498 --------------------------------------------------------------- Name of contact: Chris Chrysanthou, Company Secretary Telephone number of contact: Tel. +44 (0)1249 705166 -------------------------------------
For further information:
Alliance Pharma plc + 44 (0)1249 466966 Head of Investor Relations: Cora McCallum + 44 (0)1249 705168 ir@allianceph.com + 44 (0)20 7466 Buchanan 5000 Mark Court / Sophie Wills alliancepharma@buchanan.uk.com Deutsche Numis (Nominated Adviser and + 44 (0)20 7260 Joint Broker ) 1000 Nominated Adviser: Freddie Barnfield / Duncan Monteith / Sher Shah + 44 (0)20 7597 Investec Bank plc (Joint Broker) 5970 Patrick Robb / Maria Gomez de Olea
About Alliance
Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company . Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.
We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions .
Headquartered in the UK, the Group employs around 285 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands. For more information on Alliance, please visit our website : www.alliancepharmaceuticals.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
BLRUUSRRSNUARAR
(END) Dow Jones Newswires
January 02, 2024 05:51 ET (10:51 GMT)
1 Year Alliance Pharma Chart |
1 Month Alliance Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions